IRS2 and myeloproliferative neoplasm: To evaluate the combined effects of IRS2 and JAK1/2 pharmacological inhibition in MPN primary cells, mononuclear cells isolated from peripheral blood samples obtained from four JAK2V617F and three JAK2WT MPN patients were submitted to ex vivo treatment with the IRS/IGF1R inhibitor NT157, ruxolitinib, or both drugs combined.